Haleon plc
NYSE•HLN
CEO: Mr. Brian James McNamara
板块: Healthcare
行业: Drug Manufacturers - Specialty & Generic
上市日期: 2022-07-25
Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands. It also offers various over-the-counter products comprising nasal drops, and cold, flu, and allergy relief products under Otrivine, Theraflu, and Flonase brands for respiratory issues; anti-inflammatory and pain relief products under Voltaren, Panadol, and Advil brands; and antacids and antihistamine products under TUMS, ENO, and Fenistil brands for digestive health and other issues. The company was formerly known as DRVW 2022 plc and changed its name to Haleon plc in February 2022. Haleon plc was founded in 1715 and is headquartered in Weybridge, the United Kingdom.
联系方式
The Heights, Building 5, First Floor, Weybridge, KT13 0NY, United Kingdom
44-1932-822000
市值
$46.62B
市盈率 (TTM)
23.0
55.1
股息率
1.5%
52周最高
$11.42
52周最低
$8.71
52周范围
排名34Top 27.8%
4.7
F-Score
改良版 Piotroski 分析
基于 6 年期基本面
一般 • 4.7 / 9 分
评分区间 (0-9)
8-9: 价值优异
6-7: 基本面强劲
4-5: 整体稳健
0-3: 表现疲弱
数据范围: 2020-2025
财务仪表盘
Q4 2025 数据
营业收入
$7.39B+0.00%
近4季度走势
每股收益
$0.25+0.00%
近4季度走势
自由现金流
$1.68B+0.00%
近4季度走势
2024 Annual 财报亮点
核心亮点
Organic Revenue Growth Strong Organic revenue grew 5.0% for 2024; reported revenue declined (0.6)% to £11.2bn due to FX headwinds.
Profitability and Margin Expansion Operating profit reached £2.2bn, up 10.5% reported; adjusted operating margin grew 100bps organically to 22.3%.
Deleveraging and Shareholder Returns Returned over £1bn to shareholders via buybacks and dividends; Net debt/adjusted EBITDA reduced to 2.8x.
Health Inclusivity Target Achieved Empowered over 50m people against health inclusivity goal, achieving the 2025 target one year ahead of plan.
关注风险
FX Headwinds Impact Reported Revenue Adverse foreign exchange movements caused £421m negative impact on reported revenue decline of (0.6)%.
Increased Cyber Security Threat Profile Cyber security risk increased due to rising sophistication of threats, third-party exposure, and new risks from AI adoption.
Geopolitical Instability Risk Rises Geopolitical instability risk increased reflecting ongoing conflicts and rising protectionism impacting global operations and talent movement.
Supply Chain Resilience Tested Global sourcing network faces disruption from geopolitical instability, extreme weather, and commodity volatility impacting service levels.
前瞻展望
Medium-Term Revenue Guidance Medium-term guidance targets annual organic revenue growth between 4-6% supported by portfolio strength.
2025 Profit Growth Ahead Expecting 2025 organic revenue growth of 4-6%, with organic operating profit growth anticipated to be ahead of revenue.
Continued Capital Allocation Discipline Board approved £500m capital allocation for share buybacks in 2025, balancing investment and shareholder returns.
Evolving Strategy and Culture Priorities for 2025 include continued transformation into agile business and evolving culture to capitalize on opportunities.
同行对比
营业收入 (TTM)
$244.49B
$129.66B
$30.01B
毛利率 (最新季度)
82.5%
78.3%
68.9%
关键指标
股票代码 | 市值 | 市盈率 (TTM) | 净资产收益率 (TTM) | 负债率 |
|---|---|---|---|---|
| BDX | $62.13B | 27.8 | 6.9% | 35.6% |
| TAK | $57.56B | 79.1 | 1.6% | 31.5% |
| ZTS | $55.51B | 20.6 | 58.2% | 61.4% |
长期趋势
近4季度
营业收入
净利润
经营现金流
4季度营收复合增长率
1.3%
温和增长
4季度净利润复合增长率
7.7%
盈利能力稳步提升
现金流稳定性
75%
现金流波动较大
深度研究
下次财报:2026年7月30日
每股收益:$0.29
|营业收入:$7.66B
财务数据
电话会议
财务报告
新闻
利润表
资产负债表
现金流量表
财务比率
变化率
利润表 | 过去12个月 |
|---|
无数据